Search - tctmd.com

Displaying 861 - 880 of 2446

Sort: Relevancy | Date

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

PCI and CABG Are Complementary Options for Left Main CAD, Say Experts

News Daily News

PCI and CABG Are Complementary Options for Left Main CAD, Say Experts

Michael O'Riordan

April 27, 2022

USPSTF Finalizes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF Finalizes Tougher Stance on Aspirin in Primary Prevention

April 26, 2022

COVID-19: TCTMD’s Dispatch for April Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for April Week 4

April 25, 2022

Intermittent Fasting Trial Rumbles Weight-Loss Landscape

News Daily News

Intermittent Fasting Trial Rumbles Weight-Loss Landscape

April 22, 2022

COVID-19: TCTMD’s Dispatch for April Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for April Week 3

April 18, 2022

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

News Daily News

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

April 15, 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

COVID-19: TCTMD’s Dispatch for April Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for April Week 2

April 11, 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

April 08, 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

News Conference News ACC 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

April 08, 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

News Conference News ACC 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

April 06, 2022

FLAVOUR FFR as Good as IVUS for Intermediate Coronary Stenoses

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

COVID-19: TCTMD’s Dispatch for April Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for April Week 1

April 04, 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.